Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02086513 · ClinicalTrials.gov registry record · Phase 1

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

A Phase 1 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 1
Development phase
17
Enrollment target

NCT02086513: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.

NCT02086513 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02086513, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 1
Development phase
17 participants
Enrollment target

Study Summary

This is a phase I trial of LDE225 for the treatment of steroid-refractory chronic Graft Versus Host Disease (GVHD).

Primary Outcome

Maximum tolerated dose of LDE225 when given as treatment for steroid-refractory chronic GVHD.

Interventions

  • DRUG LDE225

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2014-04
Est. Completion 2016-12
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

Why NCT02086513 stopped before completion

NCT02086513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 1 intervention - of which LDE225 is the first listed.

NCT02086513 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02086513 about?

NCT02086513 is a clinical study titled "Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT". This is a phase I trial of LDE225 for the treatment of steroid-refractory chronic Graft Versus Host Disease (GVHD).

What is the current status of trial NCT02086513?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-04. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02086513?

The interventions under investigation include: LDE225 (DRUG).

Who is sponsoring clinical trial NCT02086513?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02086513's enrollment target sits among peer trials

17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02086513, the US trial registry maintained by the National Library of Medicine. NCT02086513 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.